|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 26, 2016 ) Xanthine is a nitrogenous compound found naturally in muscle tissue, liver spleen, pancreas and other organs as well as in the urine and is formed during the degradation of adenosine monophosphate to uric acid. Methylxanthines are methylated derivatives of the xanthine family which are derived either naturally or synthetically, which includes agents such as caffeine, theophylline, aminophylline and theobromine. Aminophylline is a soluble compound of theophylline with ethylenediamine in 2:1 ratio. Theophylline and aminophylline are caffeine like drugs also called as bronchodilators and are mainly used for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). They are muscle relaxants and helps improve contraction of the diaphragm and decreases the response of the airways to irritants, along with some anti-inflammatory actions. Although mechanism of action of methylxanthines are not completely known, the Global INITIATIVE for Chronic Obstructive Lung Disease, 2012 demonstrates that they may act as nonselective phosphodiesterase inhibitor. Theophylline and aminophylline are administered either intravenously or oral. Factors such as growing incidenceof respiratory disorders across the globe and demand for cost-effective treatment options are believed to play crucial role for the growth of global theophylline and aminophylline market. Rapid innovation in the field of personalized medicine presents a huge opportunity to manufacturers of theophylline and aminophylline market. However, launch of newer agents and severe side effects associated with the therapies may restrict the market penetration of the aminophylline and theophylline drugs. The global market for theophylline and aminophylline market is segmented on basis of disease indication, end user and geography:
Segmentation by Disease Indication
Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Infant Apnea
Segmentation by End User
Hospitals
Clinics
Ambulatory surgical centers
Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1543
If beta agonist are available aminophylline and theophylline drugs are not used as a primary treatment regime for the treatment of COPD due to their lower potency and higher potential for causing serious side effects, such as seizures and abnormal heart rhythms. However these medication can be prescribed in combination with other drugs by a doctor in case of severe COPD. Rising prevalence of respiratory disorders across globe and higher affordability of the methylxanthines are expected to create revenue traction over the forthcoming years. Based on disease indications, theophylline and aminophylline market is segmented as chronic obstructive pulmonary disease, asthma and infant apnea. Chronic obstructive pulmonary disease (COPD) disease indication segment is foreseen to lead the market. In addition, adoption of new technologies coupled with availability of high number of generic drugs for the treatment of asthma and COPD also stimulates the growth of theophylline and aminophylline market.
On the basis of end user, the global aminophylline and theophylline market has been segmented into hospitals, clinics, and ambulatory surgical centers. Hospital end user segment is anticipated to contribute the maximum share among end users.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1543
On the basis of geography theophylline and aminophylline market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America will continue to dominate the global theophylline and aminophylline market attributed to rising prevalence of lung diseases coupled with introduction of newer drugs. According to Centre for Disease Control and Prevention, chronic obstructive pulmonary disease (COPD) and acute lung injury are third leading cause of death in the U.S. In addition, according to American Lung Association, in 2010, approximately 134,676 deaths were reported due to COPD. Europe stands on the second position as a market leader in the global theophylline and aminophylline market attributed to rising prevalence of respiratory diseases. However, introduction of new generic drugs with greater efficacy exhibiting lesser side effects may restrict the market growth in the near future.
Theophylline And Aminophylline Market: Key players
Some of the major players in global theophylline and aminophylline market include GlaxoSmithKline plc, Altor BioScience Corporation, Ono Pharmaceutical Corporation Ltd., and Octapharma AG.
Fuego Co.
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
